Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel

Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet